ATRC atricure.com: Company Value to Revenue

Official company branding of AtriCure (ATRC)

The medtech industry is shifting toward minimally invasive procedures, a trend confirmed by the robust clinical trial pipeline of AtriCure, Inc. (ATRC). AtriCure, Inc. (ATRC) generates revenue through the sale of high-margin arrhythmia management systems, strengthening its market position via the recognition of hybrid ablation and the success of AtriClip. The EV/Sales valuation multiple demonstrates the efficiency of sales capitalization, with the parameter value equal to 4518.82.

atricure.com (ATRC): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

ATRC (AtriCure Medical): analytical breakdowns and indicator data

- current quotes and average value forecast:
- company stock capitalization data:
Fundamental company valuation:ATRC - AtriCure
Manufactured products of AtriCure Corp

To minimize risks when selecting an asset, it is necessary to assess the real value of the business. The EV/Sales ratio compares the total value of the company (Enterprise Value) with its revenue, excluding the impact of debt load. By analyzing the history of EV/Sales changes, an investor can see the market consensus regarding profitability. For AtriCure, Inc. (ATRC), a decline in this metric may indicate rising costs due to the implementation of energy-saving technologies and eco-friendly device packaging.

Direct competitors

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|STAA (STAAR Surgical) - Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio ChromaDex (NAGE)|Company Value to Revenue ZimVie Inc. ZIMV|EV/Sales Multiple ANGO (angiodynamics.com)|EV/Sales Multiple cerus.com CERS|teknova.com - EV/Sales Multiple|Enterprise Value-to-Sales Ratio Monogram Technologies Inc. (MGRM)|Sharps Technology, Inc. (STSS) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple InfuSystem Inc (INFU)|UTMD (Utah Medical Products Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple